A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD)
Diseases of the Nervous System | Mental Health & Behavioral Research | Alzheimer's Disease
What is the purpose of this trial?
This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase and whether the long-term effects of BAN2401 as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase.
Alzheimer’s Disease Research Unit (ADRU) - http://www.alzheimers.yale.edu
- Ages50 years - 90 years
- Trial withEisai Pharmaceuticals
- Start Date10/22/2019
- End Date02/23/2022
- Last Updated03/15/2020
- Study HIC#2000026162